Venatorx Pharmaceuticals Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
79
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$35M
- Investors
-
10
Venatorx Pharmaceuticals General Information
Description
Developer of antibacterial and antiviral drugs designed to treat multi-drug-resistant bacterial infections. The company employs novel chemical approaches to treat multidrug-resistant bacterial infections and hard-to-treat viral infections by developing medicines that exhibit selective and potent in vitro activity against both serine and beta-lactamases, thereby enabling healthcare professionals and doctors to provide patients with access to broad-spectrum treatment options that address unmet medical needs.
Contact Information
Website
www.venatorx.comCorporate Office
- 74 East Swedesford Road
- Suite 100
- Malvern, PA 19355
- United States
Corporate Office
- 74 East Swedesford Road
- Suite 100
- Malvern, PA 19355
- United States
Venatorx Pharmaceuticals Timeline
Venatorx Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Later Stage VC | 13-Jul-2023 | $35M | Completed | Clinical Trials - Phase 3 | ||
| 14. Later Stage VC (Series C1) | 22-Dec-2022 | Completed | Clinical Trials - Phase 3 | |||
| 13. Later Stage VC (Series C) | 04-Apr-2022 | Completed | Clinical Trials - Phase 3 | |||
| 12. Grant | 10-Mar-2022 | Completed | Clinical Trials - Phase 3 | |||
| 11. Grant | 24-May-2021 | Completed | Clinical Trials - Phase 3 | |||
| 10. Grant | 04-May-2021 | Completed | Clinical Trials - Phase 3 | |||
| 9. Grant | 15-Dec-2020 | Completed | Clinical Trials - Phase 3 | |||
| 8. Grant | 05-Sep-2019 | Completed | Clinical Trials - Phase 3 | |||
| 7. Grant | 28-Feb-2019 | $22.3M | $45.4M | Completed | Clinical Trials - Phase 3 | |
| 6. Grant | 22-Aug-2018 | $1.49M | $45.4M | Completed | Clinical Trials - Phase 3 |
Venatorx Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-1 | ||||||||
| Junior | ||||||||
| Series C | ||||||||
| Series B | 348,416 | $0.000100 | $35.35 | $35.35 | 1x | $13.77 | 4.75% | |
| Series A | 146,712 | $0.000100 | $13.26 | $13.26 | 1x | $7.4 | 1.4% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Venatorx Pharmaceuticals Comparisons
Industry
Financing
Details
Venatorx Pharmaceuticals Competitors (34)
One of Venatorx Pharmaceuticals’s 34 competitors is NovaBiotics, a Venture Capital-Backed company based in Aberdeen, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NovaBiotics | Venture Capital-Backed | Aberdeen, United Kingdom | ||||
| Antabio | Venture Capital-Backed | Labege, France | ||||
| Visterra | Venture Capital-Backed | Waltham, MA | ||||
| Eligo Bioscience | Venture Capital-Backed | Paris, France | ||||
| Enterome | Venture Capital-Backed | Paris, France |
Venatorx Pharmaceuticals Patents
Venatorx Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025111328-A1 | Citrate coordination complex of an orally-delivered beta-lactamase inhibitor and uses thereof | Inactive | 21-Nov-2023 | ||
| WO-2025106525-A1 | Penicillin-binding protein inhibitors | Inactive | 14-Nov-2023 | ||
| WO-2024129963-A1 | Orally-bioavailable nucleoside analogs | Inactive | 14-Dec-2022 | ||
| WO-2023230002-A1 | Nlrp3 inflammasome inhibitors | Inactive | 23-May-2022 | ||
| US-20250228882-A1 | Orally-bioavailable nucleoside analogs | Inactive | 06-Apr-2022 | A61K31/706 |
Venatorx Pharmaceuticals Signals
Venatorx Pharmaceuticals Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AMR Action Fund | Impact Investing | Minority | ||
| Small Business Innovation Research and Small Business Technology Transfer Programs | Government | |||
| CARB-X | University | |||
| Abingworth | Venture Capital | Minority | ||
| Foresite Capital | Growth/Expansion | Minority |
Venatorx Pharmaceuticals FAQs
-
When was Venatorx Pharmaceuticals founded?
Venatorx Pharmaceuticals was founded in 2010.
-
Where is Venatorx Pharmaceuticals headquartered?
Venatorx Pharmaceuticals is headquartered in Malvern, PA.
-
What is the size of Venatorx Pharmaceuticals?
Venatorx Pharmaceuticals has 79 total employees.
-
What industry is Venatorx Pharmaceuticals in?
Venatorx Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Venatorx Pharmaceuticals a private or public company?
Venatorx Pharmaceuticals is a Private company.
-
What is Venatorx Pharmaceuticals’s current revenue?
The current revenue for Venatorx Pharmaceuticals is .
-
How much funding has Venatorx Pharmaceuticals raised over time?
Venatorx Pharmaceuticals has raised $139M.
-
Who are Venatorx Pharmaceuticals’s investors?
AMR Action Fund, Small Business Innovation Research and Small Business Technology Transfer Programs, CARB-X, Abingworth, and Foresite Capital are 5 of 10 investors who have invested in Venatorx Pharmaceuticals.
-
Who are Venatorx Pharmaceuticals’s competitors?
NovaBiotics, Antabio, Visterra, Eligo Bioscience, and Enterome are some of the 34 competitors of Venatorx Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process